Gabriela Alves De Souza

Ms. Gabriela Alves De Souza

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GSGabriela Alves De Souza
Gabriela Alves De Souza
LCLorrane de Souza Chaves
Lorrane de Souza Chaves
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
JLJorge Lucas F. Lacerda
Jorge Lucas F. Lacerda
PPPaulo Pitasse-Santos
Paulo Pitasse-Santos
Marco Edilson Freire De LimaMarco Edilson Freire De Lima
Marco Edilson Freire De Lima
Background: Anticancer therapies represent the primary treatment option for a significant number of cancer patients globally; however, many of these treatments are associated with severe side effects as they target molecular structures present in both cancerous and healthy cells. In a similar context, the treatment of Chagas disease, a neglected tropical illness, is hindered by the high toxicity of the currently available drugs. Researchers are increasingly focusing on the development of safer and more selective alternatives, with natural compounds being studied as potential starting points for the creation of more effective drug candidates with a favorable therapeutic index. Objectives: The aim of this study was to design simplified curcumin-derived structures that preserved or enhanced their therapeutic activity against human lung cancer cell lines and T. cruzi, while also improving bioavailability and minimizing toxicity. Methods: In this study, curcumin and two natural curcuminoids inspired the synthesis of a chalcone and a set of bis-chalcones, compound classes known for their enhanced stability compared with their natural parent derivatives. The synthetic strategy used was the acid-catalyzed aldol condensation reaction. The stability profiles, IC50 values against A549 and H460 tumor cell lines, and trypanocidal activity against T. cruzi amastigotes of these derivatives were assessed. Results: The synthesized derivatives exhibited improved stability compared with the parent compounds, along with lower IC50 values in both A549 and H460 tumor cell lines. Additionally, one of the new analogs showed promising trypanocidal activity against T. cruzi amastigotes. Conclusions: This study provides a potential pathway toward the development of more effective and less toxic treatments for both cancer and Chagas disease. The simplified curcumin derivatives represent a promising foundation for designing new therapeutic agents with improved bioavailability and efficacy.

27 January 2022 in Molbank
Verified
Journal Article
Open access
PDF file
AFONSO SANTINE MAGALHAES MESQUITA VELEZAFONSO SANTINE MAGALHAES MESQUITA VELEZ
AFONSO SANTINE MAGALHAES MESQUITA VELEZ
GSGabriela Alves De Souza
Gabriela Alves De Souza
PPPaulo Pitasse-Santos
Paulo Pitasse-Santos
DPDouglas Chaves de Alcantara Pinto
Douglas Chaves de Alcantara Pinto
Debora Decote-RicardoDebora Decote-Ricardo
Debora Decote-Ricardo
Marco Edilson Freire De LimaMarco Edilson Freire De Lima
Marco Edilson Freire De Lima
Nitroimidazoles are pharmacophoric groups responsible for important antiparasitic activity against several infectious diseases. 2-Nitroimidazoles are found in some antiparasitic drugs and are one of the main moieties responsible for the biological activities exhibited. As an example, we can mention the drug benznidazole, the only drug available in Brazil for the treatment of Chagas disease. This work describes an efficient methodology for the synthesis of 2-nitro-1-vinyl-1H-imidazole through a simple and direct approach, as well as its full characterization and biological assessment. The antiparasitic evaluation of 2-nitro-1-vinyl-1H-imidazole against Trypanosoma cruzi (Tulahuen C2C4-LacZ strain) showed IC50 = 4.8 μM on amastigotes and low cytotoxicity against LLC-MK2 cells (IC50 > 500 μM), validating 2-nitro-1-vinyl-1H-imidazole as a biologically active structural subunit for anti-T. cruzi activity. The results presented herein demonstrate that 2-nitro-1-vinyl-1H-imidazole can be easily obtained, possessing great potential for use in the design of new antichagasic drugs through a molecular hybridization strategy using known coupling reactions.